Inflammatory Signaling Pathways in the Treatment of Alzheimer's Disease with Inhibitors, Natural Products and Metabolites (Review)

Overview

Journal Int J Mol Med

Specialty Genetics

Date 2023 Oct 6

PMID 37800614

Authors

Yujia Zheng

Xiaolu Zhang

Ruifeng Zhang

Ziyu Wang

Jiali Gan

Qing Gao

Lin Yang

Pengjuan Xu

Xijuan Jiang

Affiliations

Soon will be listed here.

Abstract

The intricate nature of Alzheimer's disease (AD) pathogenesis poses a persistent obstacle to drug development. In recent times, neuroinflammation has emerged as a crucial pathogenic mechanism of AD, and the targeting of inflammation has become a viable approach for the prevention and management of AD. The present study conducted a comprehensive review of the literature between October 2012 and October 2022, identifying a total of 96 references, encompassing 91 distinct pharmaceuticals that have been investigated for their potential impact on AD by inhibiting neuroinflammation. Research has shown that pharmaceuticals have the potential to ameliorate AD by reducing neuroinflammation mainly through regulating inflammatory signaling pathways such as NF‑κB, MAPK, NLRP3, PPARs, STAT3, CREB, PI3K/Akt, Nrf2 and their respective signaling pathways. Among them, tanshinone IIA has been extensively studied for its anti‑inflammatory effects, which have shown significant pharmacological properties and can be applied clinically. Thus, it may hold promise as an effective drug for the treatment of AD. The present review elucidated the inflammatory signaling pathways of pharmaceuticals that have been investigated for their therapeutic efficacy in AD and elucidates their underlying mechanisms. This underscores the auspicious potential of pharmaceuticals in ameliorating AD by impeding neuroinflammation.

Citing Articles

Neurodegenerative diseases and neuroinflammation-induced apoptosis.

Huang S, Lu Y, Fang W, Huang Y, Li Q, Xu Z Open Life Sci. 2025; 20(1):20221051.

PMID: 40026360 PMC: 11868719. DOI: 10.1515/biol-2022-1051.

Spatiotemporal Dysregulation of Neuron-Glia Related Genes and Pro-/Anti-Inflammatory miRNAs in the Mouse Model of Alzheimer's Disease.

Ianni M, Corraliza-Gomez M, Costa-Coelho T, Ferreira-Manso M, Inteiro-Oliveira S, Aleman-Serrano N Int J Mol Sci. 2024; 25(17).

PMID: 39273422 PMC: 11394861. DOI: 10.3390/ijms25179475.

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.

Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L Signal Transduct Target Ther. 2024; 9(1):211.

PMID: 39174535 PMC: 11344989. DOI: 10.1038/s41392-024-01911-3.

Neuroinflammation and Neurodegenerative Diseases: How Much Do We Still Not Know?.

Balistreri C, Monastero R Brain Sci. 2024; 14(1).

PMID: 38248234 PMC: 10812964. DOI: 10.3390/brainsci14010019.

References

Wang B, Shi J, Ge N, Ou Z, Tian Y, Jiang T . PM2.5 exposure aggravates oligomeric amyloid beta-induced neuronal injury and promotes NLRP3 inflammasome activation in an in vitro model of Alzheimer's disease. J Neuroinflammation. 2018; 15(1):132. PMC: 5932821. DOI: 10.1186/s12974-018-1178-5. View

Ju I, Huh E, Kim N, Lee S, Choi J, Hong J . Artemisiae Iwayomogii Herba inhibits lipopolysaccharide-induced neuroinflammation by regulating NF-κB and MAPK signaling pathways. Phytomedicine. 2021; 84:153501. DOI: 10.1016/j.phymed.2021.153501. View

Zou Y, Hong B, Fan L, Zhou L, Liu Y, Wu Q . Protective effect of puerarin against beta-amyloid-induced oxidative stress in neuronal cultures from rat hippocampus: involvement of the GSK-3β/Nrf2 signaling pathway. Free Radic Res. 2012; 47(1):55-63. DOI: 10.3109/10715762.2012.742518. View

Just P, Charawi S, Denis R, Savall M, Traore M, Foretz M . Lkb1 suppresses amino acid-driven gluconeogenesis in the liver. Nat Commun. 2020; 11(1):6127. PMC: 7705018. DOI: 10.1038/s41467-020-19490-6. View

Billod J, Lacetera A, Guzman-Caldentey J, Martin-Santamaria S . Computational Approaches to Toll-Like Receptor 4 Modulation. Molecules. 2016; 21(8). PMC: 6274477. DOI: 10.3390/molecules21080994. View

Li N, Lee A, Whitmer R, Kivipelto M, Lawler E, Kazis L . Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010; 340:b5465. PMC: 2806632. DOI: 10.1136/bmj.b5465. View

Zhu X, Raina A, Rottkamp C, Aliev G, Perry G, Boux H . Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem. 2001; 76(2):435-41. DOI: 10.1046/j.1471-4159.2001.00046.x. View

Liu Y, Li D, Jiang Q, Zhang Q, Liu P, Wang L . (3R, 7R)-7-Acetoxyl-9-Oxo-de-O-Methyllasiodiplodin, a Secondary Metabolite of Penicillium Sp., Inhibits LPS-Mediated Inflammation in RAW 264.7 Macrophages through Blocking ERK/MAPKs and NF-κB Signaling Pathways. Inflammation. 2019; 42(4):1463-1473. DOI: 10.1007/s10753-019-01009-x. View

Dempsey C, Rubio Araiz A, Bryson K, Finucane O, Larkin C, Mills E . Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain Behav Immun. 2016; 61:306-316. DOI: 10.1016/j.bbi.2016.12.014. View

10.

Park W, Kang S, Piao Y, Pak C, Oh M, Kim J . Ethanol extract of Bupleurum falcatum and saikosaponins inhibit neuroinflammation via inhibition of NF-κB. J Ethnopharmacol. 2015; 174:37-44. DOI: 10.1016/j.jep.2015.07.039. View

11.

Barone E, Di Domenico F, Sultana R, Coccia R, Mancuso C, Perluigi M . Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med. 2012; 52(11-12):2292-301. PMC: 3377854. DOI: 10.1016/j.freeradbiomed.2012.03.020. View

12.

Mattioli R, Francioso A, DErme M, Trovato M, Mancini P, Piacentini L . Anti-Inflammatory Activity of A Polyphenolic Extract from in In Vitro and In Vivo Models of Alzheimer's Disease. Int J Mol Sci. 2019; 20(3). PMC: 6387160. DOI: 10.3390/ijms20030708. View

13.

Ahn S, Suh J, Jang Y, Kim H, Choi G, Kim E . Promotes Cell Survival via cAMP-PKA/ERK-CREB Pathway. Pharmaceuticals (Basel). 2022; 15(1). PMC: 8778899. DOI: 10.3390/ph15010073. View

14.

Liu M, Guo H, Li Z, Zhang C, Zhang X, Cui Q . Molecular Level Insight Into the Benefit of Myricetin and Dihydromyricetin Uptake in Patients With Alzheimer's Diseases. Front Aging Neurosci. 2020; 12:601603. PMC: 7645199. DOI: 10.3389/fnagi.2020.601603. View

15.

Abe Y, Ikegawa N, Yoshida K, Muramatsu K, Hattori S, Kawai K . Behavioral and electrophysiological evidence for a neuroprotective role of aquaporin-4 in the 5xFAD transgenic mice model. Acta Neuropathol Commun. 2020; 8(1):67. PMC: 7218576. DOI: 10.1186/s40478-020-00936-3. View

16.

Bitner R, Markosyan S, Nikkel A, Brioni J . In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease. Neuropharmacology. 2010; 60(2-3):460-6. DOI: 10.1016/j.neuropharm.2010.10.026. View

17.

Chen J, Yin W, Tu Y, Wang S, Yang X, Chen Q . L-F001, a novel multifunctional ROCK inhibitor, suppresses neuroinflammation in vitro and in vivo: Involvement of NF-κB inhibition and Nrf2 pathway activation. Eur J Pharmacol. 2017; 806:1-9. DOI: 10.1016/j.ejphar.2017.03.025. View

18.

Ardura-Fabregat A, Boddeke E, Boza-Serrano A, Brioschi S, Castro-Gomez S, Ceyzeriat K . Targeting Neuroinflammation to Treat Alzheimer's Disease. CNS Drugs. 2017; 31(12):1057-1082. PMC: 5747579. DOI: 10.1007/s40263-017-0483-3. View

19.

Ahn S, Jang D, Park S, An S, Shin J, Han B . Cyclin-Dependent Kinase 5 Inhibitor Butyrolactone I Elicits a Partial Agonist Activity of Peroxisome Proliferator-Activated Receptor γ. Biomolecules. 2020; 10(2). PMC: 7072624. DOI: 10.3390/biom10020275. View

20.

Mizuno M, Yamada K, Maekawa N, Saito K, Seishima M, Nabeshima T . CREB phosphorylation as a molecular marker of memory processing in the hippocampus for spatial learning. Behav Brain Res. 2002; 133(2):135-41. DOI: 10.1016/s0166-4328(01)00470-3. View